Bank of New York Mellon Corp Grows Stock Holdings in Abbott Laboratories $ABT

Bank of New York Mellon Corp lifted its holdings in Abbott Laboratories (NYSE:ABT) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,926,170 shares of the healthcare product maker’s stock after acquiring an additional 247,657 shares during the period. Bank of New York Mellon Corp’s holdings in Abbott Laboratories were worth $1,619,520,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. Harbor Capital Advisors Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth approximately $27,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories in the 3rd quarter worth approximately $31,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the third quarter valued at approximately $33,000. Finally, Leonteq Securities AG purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ABT shares. Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. Oppenheimer decreased their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Argus dropped their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Finally, BTIG Research reiterated a “buy” rating and issued a $131.00 price target on shares of Abbott Laboratories in a research note on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $87.02 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $151.57 billion, a price-to-earnings ratio of 24.38, a price-to-earnings-growth ratio of 1.46 and a beta of 0.63. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The business has a 50 day simple moving average of $94.07 and a 200-day simple moving average of $110.31.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the company posted $1.09 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Activity

In related news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction dated Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.